
Yissum is proud to announce a new novel technology for the 3D printing of drug capsules. The technology is based on custom-printed 3D hydrogels with delayed release characteristics. It will was at the 2nd annual 3d Printing and Beyond...

October 24, 2018 – Jerusalem – Yissum, the technology transfer company of The Hebrew University of Jerusalem, launched its pioneering Express Licensing Campaign at the ITTN’s 5th biennial conference: Tech Transfer 4.O: Reinventing Technology...

October 9, 2018 – Jerusalem – Yissum, The Technology Transfer Company of The Hebrew University of Jerusalem, announced today the launch of its new NanoTech Fund which will focus exclusively on promising innovations emerging from Hebrew...

June 12, 2018-Yissum, the Technology Transfer Company of The Hebrew University of Jerusalem, announced a strategic collaboration with GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured. Under the...

The Business Leadership Forum hosted by Hebrew University was an incredible show of growth and innovation! Led and moderated by Dr. Yaron Daniely, CEO & President of Yissum, HU researchers presented their entrepreneurial ideas to a panel of...

May 9, 2018 – Jerusalem – Today, the Japanese giant, Canon Inc. announced its acquisition of BriefCam, the industry’s leading provider of Video Synopsis® solutions, which is based on technology developed at The Hebrew University of Jerusalem. The...

May 8, 2018 – Jerusalem – Yissum, The Technology Transfer Company of The Hebrew University of Jerusalem, in collaboration with its seed investment fund AgrInnovation, today announced the launch of HUGrow, a new food and ag-tech accelerator...

JERUSALEM, ISRAEL – Future Meat Technologies has announced a $2.2 million seed investment round co-led by Tyson Ventures, the venture capital arm of Tyson Foods. Tyson Foods is a Fortune 100 company, and one of the world’s largest food...

Jerusalem, Israel, February 6, 2018 – Merck, a leading science and technology company, today inaugurated a new technology innovation laboratory at its subsidiary Qlight Nanotech in Jerusalem, hosted on the Hebrew University’s Edmund J. Safra...

NewStem, introduces a novel technology for predicting resistance to chemotherapy treatments. The Company is developing a diagnostic kit based on the pioneering research of Professor Nissim Benvenisty, the Azrieli Center for Stem Cells and Genetic...

Therapix Biosciences Ltd. (NASDAQ, TASE: TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based drugs, today announced that it has signed a sublicense agreement for Yissum Research...

Clinical data showed superior efficacy & similar safety of MM-II vs. standard of care (hyaluronic acid) for treatment of pain in osteoarthritis
Sun Pharma to fund further development of MM-II including completion of Phase 2 and Phase 3 clinical...